Outwit investments completed the comprehensive tender offer and became the main shareholder of the company.
Completion of very significant asset acquisition (VSA), acquisition of Yuanda Pharmaceutical (China) Co., Ltd. (formerly Wuhan Yuanda Pharmaceutical Group)
Complete the sale of very important assets, and sell the company’s original Apollo business and related assets.
Opened offer to quality shareholders at a subscription price of HK$ 0.58 per offer share on the basis of one offer share for every three existing shares held payable in full on application, and thus raised funds of HK$ 278 million
Entered into an exclusive license agreement with Swiss-based R&D company Glenmark Specialty S.A., thereby the Group being licensed to exclusively sell Ryaltrisin China for a period of 20 years
Entered into an exclusive licensing and co-development agreement with Griffith University in Australia, pursuant to which the Group obtained the global development and commercialization rights for the world-wide first developed product for the treatment of parainfluenza infection
Entered into a tripartite intellectual property licensing agreement and related R&D project assignment with Sirtex and Australian National University, concerning the HIP project for the treatment of sepsis
Entered into a technology transfer agreement with Chongqing AnTi New Bio-technology Limited and obtained all rights of technical and intellectual property around the world for the world-wide first developed drug APAD
Entered into a product licensing agreement with Cloudbreak Bio-Pharmaceutical Science and Technology (Guangzhou) Co., Ltd. and CloudBreak Therapeutics LLC, and acquired approximately 6.5% interest of the enlarged share capital of Cloudbreak Pharmaceutical Inc.
Entered into an investment agreement with a Belgium company eTheRNA Immunotherapies NV and will obtain its 12% Preferred Series B Shares. Also agreed certain terms with eTheRNA for strategic cooperation and subject to further negotiation, including the exclusive development and commercialization rights in Greater China of its R&D projects
Invested in CNCB Grand Pham Healthcare Fund , with the proposed capital commitment of the Group amounted to US$50 million. The Fund intends to raise a total of US$200 million, for investing in the world’s leading pharmaceutical companies and medical device manufacturers
The Group entered into an equity investment agreement with with Shanghai Revolmmune Therapeutics Biotechnology Limited, pursuant to which the Group will invest RMB30,000,000 into Revolmmune to obtain approximately 9.7% equity interests, and obtain the exclusive global rights for the innovative product VSV-GPM for the treatment of colorectal cancer, and also the pre-emptive rights of cooperation for other products developed by Revolmmune
The Group shall invest in the third-generation stent retriever and its ancillary products for the treatment of cerebral stroke, and contribute RMB 51,000,000 to the Nanjing Fund to invest in future projects relating to healthcare, pharmaceutical and medical devices, etc.